An observational study in Nonvalvular Atrial Fibrillation, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-17.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Atrial Fibrillation by Bayer — 1 open to participants now, 1 under way, none of them phase 3. Atrial Fibrillation · Bayer.
Among the 64 studies in Atrial Fibrillation by Bayer, this one is the 10th largest by enrollment of the 51 observational ones that give a count, is one of 6 that started in 2017, is one of 51 observational ones, and was the 46th registered.
4,009 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →1 of the 64 studies in Atrial Fibrillation by Bayer is open now, in 8 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
By country, each count listing its studies:
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78,517 is above the median of 300 across 1,400 observational studies indexed under Atrial Fibrillation.
Median enrollment 100 across the 13 interventional studies, 3,055 across the 51 observational. Of the 61 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 64 studies in Atrial Fibrillation by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday clinical practice.
The primary objective in this study was to evaluate the combined end point of stroke or systemic embolism (SSE), and major bleeding in NVAF patients treated with rivaroxaban vs. VKA.
The source population of this study will be all the insured individuals included in the Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases (Truven MarketScan).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Patients who initiated OAC treatment with VKA
Drug: Vitamin K antagonist (VKA)
15/20 mg
Individually adjusted dose
Stroke or systemic embolism (SSE)
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Major bleeding
Without access to clinical information and event adjudication in administrative claims data, major bleeding will operationalized as hospital-related bleeding using a clinically validated algorithm
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Hemorrhagic stroke
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Ischemic stroke
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Subtypes of major bleeding
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs)
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Acute kidney injury
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Renal impairment
Time frame: Retrospective analysis from January 1, 2011 to December 31, 2017
Ran from Dec 2017 to primary completion in Aug 2019, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.